BRPI0606278B1 - Aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica - Google Patents
Aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica Download PDFInfo
- Publication number
- BRPI0606278B1 BRPI0606278B1 BRPI0606278-4A BRPI0606278A BRPI0606278B1 BR PI0606278 B1 BRPI0606278 B1 BR PI0606278B1 BR PI0606278 A BRPI0606278 A BR PI0606278A BR PI0606278 B1 BRPI0606278 B1 BR PI0606278B1
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- hydrogen
- formula
- compounds
- radical
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 230000029812 viral genome replication Effects 0.000 title abstract 2
- 230000000241 respiratory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 160
- -1 1,3-dihydro-benzimidazol-2-ylidene amine Chemical class 0.000 claims abstract description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 58
- 239000001257 hydrogen Substances 0.000 claims abstract description 58
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 19
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 13
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 10
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims abstract description 5
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 4
- 230000008569 process Effects 0.000 claims abstract description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims abstract description 3
- 125000001984 thiazolidinyl group Chemical group 0.000 claims abstract description 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 92
- 239000000543 intermediate Substances 0.000 claims description 70
- 150000003254 radicals Chemical class 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 9
- 238000007126 N-alkylation reaction Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 230000006181 N-acylation Effects 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 125000000524 functional group Chemical group 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 238000006722 reduction reaction Methods 0.000 claims description 3
- 125000003172 aldehyde group Chemical group 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 55
- 241000725643 Respiratory syncytial virus Species 0.000 abstract description 19
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract description 3
- 125000002950 monocyclic group Chemical group 0.000 abstract description 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 52
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 38
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- 239000002904 solvent Substances 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 125000005843 halogen group Chemical group 0.000 description 22
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 20
- 235000019341 magnesium sulphate Nutrition 0.000 description 20
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 19
- 238000004440 column chromatography Methods 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 16
- 235000011114 ammonium hydroxide Nutrition 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 230000000840 anti-viral effect Effects 0.000 description 15
- 229910000027 potassium carbonate Inorganic materials 0.000 description 15
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 235000015320 potassium carbonate Nutrition 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 0 CCC=C(C*(*)CC(C)(C)*)N(*)*C Chemical compound CCC=C(C*(*)CC(C)(C)*)N(*)*C 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 125000001589 carboacyl group Chemical group 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 241000711920 Human orthopneumovirus Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229910010084 LiAlH4 Inorganic materials 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 150000001556 benzimidazoles Chemical class 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000002361 compost Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010956 selective crystallization Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 125000000815 N-oxide group Chemical group 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010057362 Underdose Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000005181 nitrobenzenes Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 125000006061 1,2-dimethyl-1-butenyl group Chemical group 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical class CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JFZSHXFZPVBTTQ-UHFFFAOYSA-N CC(CCC1CC[O]=C)=CC1NCC(CCC1N(C)C=C=N)=CC1NCc(nc(C)cc1)c1O Chemical compound CC(CCC1CC[O]=C)=CC1NCC(CCC1N(C)C=C=N)=CC1NCc(nc(C)cc1)c1O JFZSHXFZPVBTTQ-UHFFFAOYSA-N 0.000 description 1
- ZQGHHWPRARATOJ-UHFFFAOYSA-N CCC1C=CC2N(C)C(N)N(CC3NC(C)=CC=C3C=C)C2C1 Chemical compound CCC1C=CC2N(C)C(N)N(CC3NC(C)=CC=C3C=C)C2C1 ZQGHHWPRARATOJ-UHFFFAOYSA-N 0.000 description 1
- AHTURPVQCJFMDP-UHFFFAOYSA-N CCOC(C1C(C2)C2C2N(CC3NC(C)=CC=C3N=O)C(N)N(C)C2CC1)O Chemical compound CCOC(C1C(C2)C2C2N(CC3NC(C)=CC=C3N=O)C(N)N(C)C2CC1)O AHTURPVQCJFMDP-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124679 RSV vaccine Drugs 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000004973 alkali metal peroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
cada Alk independentemente é C1-6 alcanodiila;
Q é hidrogênio; C1-6 alquila substituída com um ou dois radicais de Ar2; C1-6 alquila substituída com quinolinila, oxazolidinila, tiazolidinila, morfolinila, tiomorfolinila, ou com pirrolidinonila; -CO-Ar2; ou Q é um radical de fórmulaem que t é 1,2 ou 3;
R4 é amino, mono ou di(C1-6alquil)amino;
R1 é Ar2, -CO-Ar2 ou um heterociclo monocíclico ou bicíclico selecionado de piperidinila, piperazinila, morfolinila, tiomorfolinila, piridila, pirazinila, piridazinila, pirimidinila, furanila, tetraidrofuranila, tienila, pirrolila, tiazolila, oxazolila, imidazolila, isotiazolila, pirazolila, isoxazolila, oxadiazolila, quinolinila, quinoxalinila, benzofuranila, benzotienila, benzimidazolila, benzoxazolila, benztiazolila, piridopiridila, naftiridinila, 1 H-imidazo[4,5-b]piridinila, 3H-imidazo[4,5-b]piridinila,
imidazo[1,2-a]piridinila e 2,3-diidro-1,4-dioxino[2,3-b]piridila; em que cada dos referidos heterociclos monocíclicos ou bicíclicos podem opcionalmente ser substituídos com 1, 2, ou 3 substituintes cada qual independentemente, selecionado do grupo consistindo em halo, hidróxi, amino, ciano, carboxila, C1-6 alquila, C1-6 alquilóxi, C1-6 alquiltio, C1-6alquilóxiC1-6alquila, hidróxiC1-6alquila, mono ou di(C1-6 alquil)amino, mono ou di(C1-6 alquil)aminoC1-6alquila, polihaloC1-6alquila, C1-6 alquilcarbonilamino, C1-6 alquil-oxicarbonila e -C(=O)-
NR5aR5b;
R2 independentemente, tem os mesmos significados de R1 e adicionalmente pode ser hidrogênio;
onde Q é diferente de hidrogênio, R3 é hidrogênio; ou onde Q é hidrogênio, R3 é um radical de fórmula:em que
R6 é selecionado de hidrogênio, C1-6 alquila, Ar2C1-6 alquila, hidróxiC1-6alquila, (C1-6alquilóxi)-C1-6alquila, aminoC1-6alquila, mono e di(C1-6alquil)amino-C1-6alquila, carboxilC1-6alquila, C1-6alquiloxicarbonilC1-6alquila, aminocarbonilC1-6alquila, mono e di(C1-6alquil)aminocarbonilCi-6alquila;
R7, R8, R9 cada qual independentemente, é selecionado de halo, ciano, C1-6 alquila, Ar1-C1-6alquila, cianoC1-6alquila, C2-6 alquenila, cianoC2-6alquenila, C2-6 alquinila, cianoC2-6alquinila, Ar1, R10a-O-, R10a-S-, -N(R5aR5b), polihaloC1-6alquila, R10a-O-C(=O)-, N(R5aR5b)-C(=O)-, R10a-O-C1-6alquila, N(R5aR5b)-C1-6alquila, R10a-O-C(=O)-C1-6alquila, N(R5aR5b)-C(=O)-C1-6alquila, R10a-C(=O)-NR5b-, R10b-C(=O)-O-, R10b-C(=O)-O-C1-6alquila; e R8 e/ou R9 podem também ser hidrogênio; cada R5a e R5b independentemente um do outro é hidrogênio ou C1-6 alquila;
R10a é hidrogênio, C1-6 alquila ou Ar1C1-6alquila;
R10b é C1-6 alquila ou Ar1C1-6alquila;
Ar1 é fenila ou fenila substituída com 1, 2, 3 ou 4 substituintes independentemente selecionados de halo, hidróxi, C1-6 alquila, hidróxiC1-6alquila, polihaloC1-6alquila e C1-6 alquilóxi;
Ar2 é fenila ou fenila substituída com 1, 2, 3 ou 4 substituintes independentemente selecionados de halo, hidróxi, C1-6 alquila, ciano, nitro, hidróxiC1-6alquila, polihaloC1-6alquila, C1-6alquilóxi, hidróxiC1-6alquilóxi, C1-6alquiloxicarbonila, Ar1 e Ar1O.
- (a) um ou mais dos radicais Alk é C1-4 alcanodiila;
- (b) em que um ou mais dos radicais Alk é C1-2 alcanodiila;
- (c) em que um ou mais dos radicais Alk é metileno; ou
- (d) em que todos os radicais Alk são metileno.
- (a) Q é C1-6 alquila substituída com um ou dois radicais Ar2; C1-6 alquila substituída com quinolinila, morfolinila ou com pirrolidinonila; -CO-Ar2; ou Q é um radical de fórmula
- (b) Q é C1-6 alquila substituída com um ou dois radicais Ar2; C1-6 alquila substituída com quinolinila, morfolinila ou com pirrolidinonila;
- (c) Q é -CO-Ar2; ou
- (d) Q é um radical de fórmula (a) em que t é 2; R4 é amino, mono ou di(C1-6 alquil)amino.
- (e) Q é hidrogênio.
- (a) R1 e/ou R2 são Ar2, -CO-Ar2 ou um heterociclo selecionado de piperidinila, piperazinila, morfolinila, tiomorfolinila, piridila, pirazinila, pirimidinila, furanila, tetraidrofuranila, tienila, pirrolila, tiazolila, oxazolila, imidazolila, quinolinila, quinoxalinila, benzofuranila, benzotienila, benzimidazolila, benzoxazolila, benztiazolila em que cada dos referidos heterociclos pode opcionalmente ser substituído com 1, 2, ou 3 substituintes cada qual independentemente, selecionado de halo, hidróxi, amino, ciano, carboxila, C1-6 alquila, C1-6 alquilóxi, C1-6alquilóxiC1-6alquila, hidróxiC1-6 alquila, mono ou di(C1-6 alquil)amino; ou em que
- (b) R1 e/ou R2 são Ar2, -CO-Ar2, ou um heterociclo selecionado de morfolinila, piridila, pirazinila, pirimidinila, furanila, tetraidrofuranila, tienila, tiazolila, oxazolila, imidazolila e quinolinila; em que cada dos referidos heterociclos pode opcionalmente ser substituído com 1 ou 2 substituintes independentemente, selecionado de halo, hidróxi, amino, ciano, C1-6 alquila e C1-6 alquilóxi; ou em que
- (c) R1 e/ou R2 são Ar2, -CO-Ar2, morfolinila, piridila ou quinolinila; em que cada dos referidos heterociclos pode opcionalmente ser substituído com 1 ou 2 substituintes independentemente, selecionado de hidróxi e C1-6 alquila; ou em que
- (d) R1 e/ou R2 são Ar2, -CO-Ar2, morfolinila ou quinolinila.
- (a) R3 é hidrogênio e Q é diferente de hidrogênio;
- (b) R3 é um radical de fórmula:
R6 é selecionado de hidrogênio, C1-6 alquila, Ar2C1-6 alquila, hidróxiC1-6 alquila, (C1-6 alquilóxi)C1-6 alquila, aminoC1-6 alquila, carboxilC1-6 alquila, aminocarbonil-C1-6 alquila;
R7, R8, R9 independentemente, um do outro são selecionados de halo, ciano, C1-6 alquila, cianoC1-6 alquila, R10a-O-, -N(R5aR5b), trifluorometila, R10a-O-C(=O)-, N(R5aR5b)-C(=O)-, R10a-O-C1-6 alquila, N(R5aR5b)-C1-6 alquila, R10a-O-C(=O)-C1-6 alquila, N(R5aR5b)-C(=O)-C1-6 alquila, R10b-C(=O)-O-, R10b-C(=O)-O-C1-6 alquila; e R8 e/ou R9 podem também ser hidrogênio; cada R5a e R5b independentemente, um do outro é hidrogênio ou C1-6 alquila;
R10a é hidrogênio ou C1-6 alquila;
R10b é C1-6 alquila; ou em que
(c) R3 é um radical de fórmula (b) em que
R6 é selecionado de hidrogênio, C1-6 alquila, hidróxiC1-6 alquila, aminoC1-6 alquila, carboxilC1-6 alquila e aminocarbonilC1-6 alquila;
R7, R8, R9 independentemente, um do outro são selecionados de halo, ciano, C1-6 alquila, cianoC1-6 alquila, R10a-O-, -N(R5aR5b), R10a-O-C(=O)-, N(R5aR5b)-C(=O)-, R10a-O-C1-6 alquila,N(R5aR5b)-C1-6 alquila, R10a-O-C(=O)-C1-6 alquila,
N(R5aR5b)-C(=O)-C1-6 alquila, R10b-C(=O)-O-C1-6 alquila; e R8 e/ou R9 podem também ser hidrogênio;
cada R5a e R5b independentemente, um do outro é hidrogênio ou C1-6 alquila;
R10a é hidrogênio ou C1-6 alquila;
R10b é C1-6 alquila; ou
(d) R3 é um radical de fórmula (b) em que
R6 é selecionado de hidrogênio, hidróxiC1-6 alquila, aminoC1-6 alquila e amino-carbonilC1-6 alquila;
R7, R8, R9 independentemente, um do outro são selecionados de halo, C1-6 alquila, cianoC1-6 alquila, R10a-O, -N(R5aR5b), R10a-O-C1-6 alquila, N(R5aR5b)-C1-6 alquila,
R10a-O-C(=O)-C1-6 alquila, R10b-C(=O)-O-C1-6 alquila; e R8 e/ou R9 podem também ser hidrogênio; R5a e R5b são hidrogênio;
R10a é hidrogênio ou C1-6 alquila;
R10b é C1-6 alquila; ou
(e) R3 é um radical de fórmula (b) em que
R6 é hidrogênio;
R7, R8, R9 independentemente, um do outro são selecionados de C1-6 alquila, R10a-O-C1-6 alquila, e R8 e/ou R9 podem também ser hidrogênio;
R5a e R5b são hidrogênio;
R10a é hidrogênio ou C1-6 alquila; e onde em caso de restrições (b), (c) e (d), Q é hidrogênio.
Exemplo 1
Exemplo 2
Exemplo 3
Exemplo 4
Esquema D
Exemplo 5
Exemplo 6
Esquema_F_(esquema modificado)
Exemplo 7
Claims (10)
- Composto, caracterizado pelo fato de que apresenta a fórmulasais de adição do mesmo; ou uma forma estereoquimicamente isomérica do mesmo ou uma forma tautomérica do mesmo; em que cada Alk independentemente, é C1-6 alcanodiila;
Q é hidrogênio; C1-6 alquila substituída com um ou dois radicais Ar2; C1-6 alquila substituída com quinolinila, oxazolidinila, tiazolidinila, morfolinila, tiomorfolinila, ou com pirrolidinonila; -CO-Ar2; ou Q é um radical de fórmulaem que t é 1,2 ou 3;
R4 é amino, mono ou di(C1-6 alquil)amino;
R1 é quinolinila;
R2 é Ar2, -CO-Ar2, morfolinila ou quinolinila; onde Q é diferente de hidrogênio, R3 é hidrogênio; ou onde Q é hidrogênio, R3 é um radical de fórmula:em que
R6 é selecionado de hidrogênio, C1-6 alquila, Ar2C1-6 alquila, hidróxiC1-6 alquila, (C1-6 alquilóxi)C1-6 alquila, aminoC1-6 alquila, mono e di(C1-6 alquil)amino-C1-6 alquila, carboxilC1-6 alquila, C1- 6alquiloxicarbonilC1-6 alquila, aminocarbonil-C1-6 alquila, mono e di(C1-6 alquil)aminocarbonilC1-6 alquila;
R7, R8, R9 cada qual independentemente, são selecionados de halo, ciano, C1-6alquila, Ar1C1-6 alquila, cianoC1-6 alquila, C2-6 alquenila, cianoC2-6 alquenila, C2-6 alquinila, cianoC2-6 alquinila, Ar1, R10a-O-, R10a-S-, -N(R5aR5b), polihaloC1-6alquila, R10a-O-C(=O)-, N(R5aR5b)-C(=O)-, R10a-O-C1-6 alquila, N(R5aR5b)-C1-6 alquila, R10a-O-C(=O)-C1-6 alquila, N(R5aR5b)-C(=O)-C1-6 alquila, R10a-C(=O)-NR5b-, R10b-C(=O)-O-, R10b-C(=O)-O-C1-6 alquila; e R8 e/ou R9 podem também ser hidrogênio;
cada R5a e R5b independentemente, um do outro são hidrogênio ou C1-6 alquila;
R10a é hidrogênio, C1-6 alquila ou Ar1C1-6 alquila;
R10b é C1-6 alquila ou Ar1C1-6 alquila;
Ar1 é fenila ou fenila substituída com 1, 2, 3 ou 4 substituintes independentemente selecionados de halo, hidróxi, C1-6 alquila, hidróxiC1-6 alquila, polihaloC1-6 alquila e C1-6 alquilóxi;
Ar2 é fenila ou fenila substituída com 1, 2, 3 ou 4 substituintes independentemente, selecionado de halo, hidróxi, C1-6 alquila, ciano, nitro, hidróxiC1-6 alquila, polihaloC1-6 alquila, C1-6 alquilóxi, hidróxiC1-6 alquilóxi, C1-6 alquiloxicarbonila, Ar1 e Ar1O. - Composto de acordo com a reivindicação 1 caracterizado pelo fato de que Q é hidrogênio; C1-6 alquila substituída com um ou dois radicais Ar2; C1-6 alquila substituída com quinolinila, morfolinila ou com pirrolidinonila; -CO-Ar2; ou Q é um radical de fórmulaem que t é 2; R4 é amina, mono ou di(C1-6 alquil)amino.
- Composto de acordo com a reivindicação 1, caracterizado pelo fato de que Q é hidrogênio.
- Composto de acordo com a reivindicação 1, caracterizado pelo fato de que Q é C1-6 alquila substituída com um ou dois radicais Ar2; C1-6 alquila substituída com quinolinila, morfolinila ou com pirrolidinonila;
Q é -CO-Ar2; ou
Q é um radical de fórmula (a) em que t é 2; R4 é amina, mono ou di(C1-6 alquil)amino. - Composto de acordo com qualquer uma das reivindicações 1 a 4, caracterizado pelo fato de R3 é um radical de fórmula (b) em que
R6 é selecionado de hidrogênio, hidróxiC1-6 alquila, aminoC1-6 alquila e aminocarbonilC 1-6alquila;
R7, R8, R9 independentemente, um do outro são selecionados de halo, C1-6 alquila, cianoC1-6 alquila, R10a-O-, -N(R5aR5b), R10a-O-C 1-6alquila, N(R5aR5b)-C1-6 alquila, R10a-O-C(=O)-C1-6 alquila, R10b-C(=O)-O-C1-6 alquila; e R8 e/ou R9 podem também ser hidrogênio;
R5a e R5b são hidrogênio;
R10a é hidrogênio ou C1-6 alquila;
R10b é C1-6 alquila. - Composto de acordo com quaisquer das reivindicações 1 a 5, caracterizado pelo fato de que R3 é hidrogênio ou um radical de fórmula (b) em que
R6 é hidrogênio;
R7, R8, R9 independentemente, um do outro são selecionados de C1-6 alquila,
R10a-O-C1-6alquila, e R8 e/ou R9 também podem ser hidrogênio;
R5a e R5b são hidrogênio;
R10a é hidrogênio ou C1-6 alquila. - Composto de acordo com quaisquer das reivindicações 1 a 6, caracterizado pelo fato de que R3 é hidrogênio.
- Composto de acordo com quaisquer das reivindicações 1 a 7, caracterizado pelo fato de ser para uso como um medicamento.
- Composição farmacêutica, caracterizado pelo fato de que compreende um veículo farmaceuticamente aceitável, e como ingrediente ativo, uma quantidade terapeuticamente eficaz de um composto como definido em qualquer uma das reivindicações 1 a 7.
- Processo para preparar um composto químico como definido em quaisquer das reivindicações 1 a 7, o referido processo caracterizado pelo fato de que compreende:
(a) N-alquilação de um benzimidazol (II) com um agente de alquilação (III) como delineado no seguinte esquema de reação:em que neste e nos seguintes esquemas de reação Q, Alk, R1, R2, R3, R4 têm os significados definidos em qualquer uma das reivindicações 1 a 7, e W representa um grupo de saída;
(b) N-alquilação ou N-acilação (onde Q é Ar2-CO-) de um benzimidazol (IV) com uma alquilação ou agente de acilação (V) como delineado no seguinte esquema de reação:(c) preparação de compostos de fórmula (I) em que R3 é um radical (b) em que o grupo Alk é metileno, cujos compostos podem ser representados pela fórmula (I-a) reduzindo-se os intermediários de fórmula (VI) em que R11 é C1-6 alquila, por uma reação de redução, a intermediários (VII) tendo um grupo hidroximetileno e oxidando-se o último grupo em um grupo aldeído (intermediários VIII) com um oxidante suave, que também pode ser derivado com aminas para os compostos de fórmula (I-a): (d) preparação de compostos de fórmula (I) em que Q é um radical (a), cujos compostos podem ser representados pela fórmula (Ib) N-alquilando os intermediários de fórmula (IX) com um reagente R4-Alk-W:(e) conversão de compostos de fórmula (I) mutuamente seguindo reações de transformação de grupo funcional conhecidas na técnica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05102127.7 | 2005-03-17 | ||
EP05102127 | 2005-03-17 | ||
PCT/EP2006/060852 WO2006097534A1 (en) | 2005-03-17 | 2006-03-17 | 1,3-dihydro-benzimidazol-2-ylidene amines as inhibitors of respiratory syncytial virus replication |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0606278A2 BRPI0606278A2 (pt) | 2009-06-09 |
BRPI0606278B1 true BRPI0606278B1 (pt) | 2020-09-08 |
BRPI0606278B8 BRPI0606278B8 (pt) | 2021-05-25 |
Family
ID=34939009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606278A BRPI0606278B8 (pt) | 2005-03-17 | 2006-03-17 | aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (1) | US7956196B2 (pt) |
EP (1) | EP1951704B1 (pt) |
JP (1) | JP5289934B2 (pt) |
CN (1) | CN101142208B (pt) |
AU (1) | AU2006224533B9 (pt) |
BR (1) | BRPI0606278B8 (pt) |
CA (1) | CA2600507C (pt) |
ES (1) | ES2574670T3 (pt) |
MX (1) | MX2007011292A (pt) |
RU (1) | RU2410382C2 (pt) |
WO (1) | WO2006097534A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070232673A1 (en) * | 2006-01-19 | 2007-10-04 | Roth Gregory P | 2-Imino-benzimidazoles |
AU2009326259A1 (en) * | 2008-12-08 | 2011-07-28 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
AU2017326359B2 (en) | 2016-09-14 | 2021-02-04 | National Chiao Tung University | Novel substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors |
EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
WO2021013733A1 (en) * | 2019-07-19 | 2021-01-28 | Abivax | Aryl-n-aryl derivatives for treating a rna virus infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4842875B1 (pt) * | 1969-01-29 | 1973-12-14 | ||
SK18942001A3 (sk) * | 1999-06-28 | 2002-10-08 | Janssen Pharmaceutica N. V. | Inhibítory replikácie respiračného syncytiálneho vírusu |
NZ515392A (en) * | 1999-06-28 | 2004-03-26 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
CN1210275C (zh) | 1999-06-28 | 2005-07-13 | 詹森药业有限公司 | 呼吸道合胞病毒复制抑制剂 |
-
2006
- 2006-03-17 AU AU2006224533A patent/AU2006224533B9/en not_active Ceased
- 2006-03-17 CN CN2006800085588A patent/CN101142208B/zh active Active
- 2006-03-17 BR BRPI0606278A patent/BRPI0606278B8/pt not_active IP Right Cessation
- 2006-03-17 MX MX2007011292A patent/MX2007011292A/es active IP Right Grant
- 2006-03-17 CA CA2600507A patent/CA2600507C/en active Active
- 2006-03-17 EP EP06708798.1A patent/EP1951704B1/en active Active
- 2006-03-17 ES ES06708798.1T patent/ES2574670T3/es active Active
- 2006-03-17 US US11/908,538 patent/US7956196B2/en active Active
- 2006-03-17 JP JP2008501332A patent/JP5289934B2/ja active Active
- 2006-03-17 RU RU2007138380/04A patent/RU2410382C2/ru active IP Right Revival
- 2006-03-17 WO PCT/EP2006/060852 patent/WO2006097534A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2006224533B9 (en) | 2012-06-21 |
EP1951704B1 (en) | 2016-03-16 |
ES2574670T3 (es) | 2016-06-21 |
BRPI0606278A2 (pt) | 2009-06-09 |
CA2600507A1 (en) | 2006-09-21 |
JP5289934B2 (ja) | 2013-09-11 |
AU2006224533A1 (en) | 2006-09-21 |
US20080146564A1 (en) | 2008-06-19 |
US7956196B2 (en) | 2011-06-07 |
BRPI0606278B8 (pt) | 2021-05-25 |
CA2600507C (en) | 2013-10-22 |
JP2008533103A (ja) | 2008-08-21 |
CN101142208A (zh) | 2008-03-12 |
AU2006224533B2 (en) | 2012-05-03 |
CN101142208B (zh) | 2012-05-23 |
WO2006097534A1 (en) | 2006-09-21 |
RU2410382C2 (ru) | 2011-01-27 |
RU2007138380A (ru) | 2009-04-27 |
EP1951704A1 (en) | 2008-08-06 |
MX2007011292A (es) | 2007-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2651903E (pt) | Inibidores benzimidazolo do vírus sincicial respiratorio | |
EP1896473B1 (en) | 1-[[2-amino-3-(substituted alkyl)-3h-benzimidazolyl]methyl]-3-subtituted-1,3-dihydro-benzoimidazol-2-ones as inhibitors of respiratory syncytial virus replication | |
BRPI0606278B1 (pt) | Aminas de 1,3-diidro-benzimidazol-2-ilideno como inibidores de replicação de vírus sincicial respiratório, seu processo de preparação e composição farmacêutica | |
ES2444690T3 (es) | Bencimidazoles sustituidos con heterociclilaminoalquilo. | |
CA2612265C (en) | 2-substituted benzimidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: TIBOTEC PHARMACEUTICALS (IE) |
|
B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2766 DE 09-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |